Abstract
Since March 2020 the coronavirus disease 2019 (COVID-19) has permanently shaped the global health care scenery. With Italy being one of the most heavily affected countries, medical oncologists had to elaborate a prompt response in order to ensure high-quality standards for diagnostic-therapeutic pathways in cancer care. Considering the clinical spectrum and potential overlap with COVID-19 disease, lung cancer (LC) patients represent a highly vulnerable population. Aim of this multicenter Italian study is to assess whether the COVID-19 outbreak has impacted on access to cancer diagnosis, staging and treatment for LC patients after March 2020 compared to pre-pandemic time.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
